vs
Beam Therapeutics Inc.（BEAM）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是Beam Therapeutics Inc.的1.7倍（$193.5M vs $114.1M），Beam Therapeutics Inc.同比增速更快（279.5% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
BEAM vs MCS — 直观对比
营收规模更大
MCS
是对方的1.7倍
$114.1M
营收增速更快
BEAM
高出276.8%
2.8%
自由现金流更多
MCS
多$113.4M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $193.5M |
| 净利润 | $244.3M | — |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 0.9% |
| 净利率 | 214.1% | — |
| 营收同比 | 279.5% | 2.8% |
| 净利润同比 | 370.4% | — |
| 每股收益（稀释后） | $2.53 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMMCS
| Q4 25 | $114.1M | $193.5M | ||
| Q3 25 | — | $210.2M | ||
| Q2 25 | — | $206.0M | ||
| Q1 25 | — | $148.8M | ||
| Q4 24 | — | $188.3M | ||
| Q3 24 | — | $232.7M | ||
| Q2 24 | — | $176.0M | ||
| Q1 24 | — | $138.5M |
净利润BEAMMCS
| Q4 25 | $244.3M | — | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $-16.8M | ||
| Q4 24 | — | $986.0K | ||
| Q3 24 | — | $23.3M | ||
| Q2 24 | — | $-20.2M | ||
| Q1 24 | — | $-11.9M |
营业利润率BEAMMCS
| Q4 25 | -15.3% | 0.9% | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | — | 6.3% | ||
| Q1 25 | — | -13.7% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 14.1% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | -12.0% |
净利率BEAMMCS
| Q4 25 | 214.1% | — | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | -11.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 10.0% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -8.6% |
每股收益（稀释后）BEAMMCS
| Q4 25 | $2.53 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $23.4M |
| 总债务越低越好 | — | $159.0M |
| 股东权益账面价值 | $1.2B | $457.4M |
| 总资产 | $1.5B | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资BEAMMCS
| Q4 25 | $1.2B | $23.4M | ||
| Q3 25 | — | $7.4M | ||
| Q2 25 | — | $14.9M | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $40.8M | ||
| Q3 24 | — | $28.4M | ||
| Q2 24 | — | $32.8M | ||
| Q1 24 | — | $17.3M |
总债务BEAMMCS
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
股东权益BEAMMCS
| Q4 25 | $1.2B | $457.4M | ||
| Q3 25 | — | $454.3M | ||
| Q2 25 | — | $448.4M | ||
| Q1 25 | — | $441.8M | ||
| Q4 24 | — | $464.9M | ||
| Q3 24 | — | $462.3M | ||
| Q2 24 | — | $449.4M | ||
| Q1 24 | — | $459.3M |
总资产BEAMMCS
| Q4 25 | $1.5B | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.0B |
负债/权益比BEAMMCS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $26.4M |
| 自由现金流率自由现金流/营收 | -76.3% | 13.6% |
| 资本支出强度资本支出/营收 | 3.3% | 11.6% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流BEAMMCS
| Q4 25 | $-83.3M | $48.8M | ||
| Q3 25 | — | $39.1M | ||
| Q2 25 | — | $31.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | $52.6M | ||
| Q3 24 | — | $30.5M | ||
| Q2 24 | — | $36.0M | ||
| Q1 24 | — | $-15.1M |
自由现金流BEAMMCS
| Q4 25 | $-87.0M | $26.4M | ||
| Q3 25 | — | $18.2M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | — | $-58.3M | ||
| Q4 24 | — | $27.1M | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $16.1M | ||
| Q1 24 | — | $-30.5M |
自由现金流率BEAMMCS
| Q4 25 | -76.3% | 13.6% | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | -39.2% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | — | -22.0% |
资本支出强度BEAMMCS
| Q4 25 | 3.3% | 11.6% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 13.5% | ||
| Q3 24 | — | 7.9% | ||
| Q2 24 | — | 11.3% | ||
| Q1 24 | — | 11.1% |
现金转化率BEAMMCS
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
